JP Morgan Chase
OBIO icon

JP Morgan Chase’s Orchestra BioMed OBIO Stock Holding History

JP Morgan Chase’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.3K Sell
4,258
-328
-7% -$1.4K ﹤0.01% 6597
2025
Q4 		$19K Buy
4,586
+4,116
+876% +$16.6K ﹤0.01% 6520
2025
Q3 		$1.17K Hold
470
– – ﹤0.01% 6973
2025
Q2 		$1.26K Sell
470
-11,482
-96% -$33.5K ﹤0.01% 6598
2025
Q1 		$51.2K Sell
11,952
-37,453
-76% -$186K ﹤0.01% 5872
2024
Q4 		$198K Buy
49,405
+38,535
+355% +$207K ﹤0.01% 5478
2024
Q3 		$55.9K Sell
10,870
-450
-4% -$2.94K ﹤0.01% 5954
2024
Q2 		$92.3K Buy
11,320
+5,124
+83% +$29.7K ﹤0.01% 5553
2024
Q1 		$32.7K Sell
6,196
-3,410
-35% -$23.1K ﹤0.01% 6088
2023
Q4 		$87.7K Hold
9,606
– – ﹤0.01% 5800
2023
Q3 		$83.8K Buy
9,606
+6,202
+182% +$41.7K ﹤0.01% 5590
2023
Q2 		$23.8K Buy
+3,404
New +$51.6K ﹤0.01% 5881

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

JP Morgan Chase's OBIO Position: Q1 2026 in Review

JP Morgan Chase reduced its Orchestra BioMed (OBIO) stake by 7.2% in Q1 2026, selling an estimated $1.4K and leaving 4,258 shares worth $17.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6597.

JP Morgan Chase first reported a position in OBIO in Q2 2023 and has held it in 12 quarters since. The position peaked at $198K in Q4 2024. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • JP Morgan Chase held 4,258 shares of Orchestra BioMed worth $17.3K as of Q1 2026.
  • JP Morgan Chase sold 328 Orchestra BioMed shares in Q1 2026, an estimated $1.4K.
  • Orchestra BioMed made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6597 holding.
  • JP Morgan Chase first reported a position in Orchestra BioMed in Q2 2023 and has held it in 12 quarters since.
  • JP Morgan Chase's Orchestra BioMed position peaked at $198K in Q4 2024.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.